Ligand id: 8274

Name: mifamurtide

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: mifamurtide

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 25
Hydrogen bond donors 10
Rotatable bonds 59
Topological polar surface area 385.91
Molecular weight 1236.75
XLogP 9.69
No. Lipinski's rules broken 4

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
The EMA granted mifamurtide orphan drug designation for the treatment of osteosarcoma in children and young adults in 2004. The drug was subsequently fully approved by the EMA in 2009. Mifamurtide is indicated for the treatment of high-grade, nonmetastasizing, resectable osteosarcoma following complete surgical removal and/or in combination with chemotherapy. Further reading: [1-2,4,6].
Mechanism Of Action and Pharmacodynamic Effects
Mifamurtide activates the pattern recognition receptor NOD2 (gene symbol NLRC2) on monocytes and macrophages, stimulating the production of pro-inflammatory cytokines. This activates an antibacterial-like immune response which kills cancer cells [5,7].
External links